Background

The three-dimensional spatial organization of the genome is a key mechanism for precise control of gene expression. The binding location of the cohesin loading factor (NIPBL), which guides cohesin to chromatin, is a critical determinant of loop formation. Previous research has focused on conserved structural proteins such as CTCF to elucidate 3D genome structure. However, this approach alone has limitations in fully explaining cell-type-specific gene activation mechanisms. The specific pathways by which NIPBL is recruited to chromatin in a tissue-specific manner have remained largely unknown.

Key Findings

The research team elucidated the molecular mechanism by which the pioneer transcription factor FOXA1 directly mediates the binding of NIPBL to chromatin, based on analyses of prostate cancer cell lines. Furthermore, they found that FOXA1 cooperates with other pioneer transcription factors, such as the ETS1 transcription factor, to precisely organize the 3D genome structure. The results showed that FOXA1 primarily directs NIPBL to the interior of topologically associating domains (TADs), activating symmetric loop extrusion, thereby forming stable genomic loops. In contrast, ETS1 directs NIPBL to TAD boundaries, promoting one-sided loop extrusion. What happens when FOXA1 is depleted? Rapid removal of FOXA1 from cells inhibited NIPBL binding to chromatin and disrupted loop structures within the domain. In particular, the effect of the FOXA1 R219S mutation, which is frequently observed in prostate cancer patients, was also confirmed. This mutant protein recognizes a non-canonical motif instead of a typical DNA sequence, misdirecting NIPBL to the TAD boundary. This disrupts the insulation of the genomic boundary, leading to a significant increase in the malignancy of cancer cells.

Significance and Prospects

This study presents a paradigm shift, demonstrating that the formation of 3D genome structure is not simply determined by the arrangement of fixed structural proteins, but is highly dynamically regulated by the activity of cell-type-specific pioneer transcription factors. In particular, the finding that mutations in specific transcription factors in cancer cells disrupt the three-dimensional physical structure of the genome and activate tumors has the potential to contribute to the discovery of therapeutic targets. However, this study primarily used prostate cancer cell lines as a model, so further research is needed to confirm whether the identified NIPBL recruitment mechanism operates in the same way in other cancers or normal tissues. The development of small molecule compounds that selectively inhibit the interaction between mutant FOXA1 and NIPBL remains a challenge to be addressed for actual clinical application.